Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace

NorDx obtains Sysmex XN-3000 analyzers, 9/13

NorDx, a large reference laboratory in Maine that is a member of MaineHealth, has acquired Sysmex America’s XN-3000 automated hematology analyzers. The XN-3000 configuration enables enhanced diagnostic capabilities and greater efficiency that transforms NorDx into an accountable care laboratory model. The Sysmex XN-3000 has a menu of advanced clinical parameters that allows NorDx and MaineHealth to conduct cellular studies that enable the quantitative assessments of red cell, white cell, and platelet precursors, guiding diagnosis and treatment by the physician. These

Canadian hospital acquires Sysmex XN-2000 hematology analyzer, 9/13

Ontario-based Brockville General Hospital and Sysmex Canada announced the hospital’s installation and implementation of a Sysmex XN-2000 automated hematology analyzer. This is the first Sysmex XN series analyzer to be installed in Canada. The compact automated hematology analyzer provides the hospital’s clinical laboratory with expanded clinical and operational capabilities to meet changing workload demands and testing complexity that may accompany an aging population, while withstanding future medical technologist shortages. The Sysmex XN series suite of products includes the XN-1000, XN-2000,

Hematology systems, middleware software, 9/13

Sysmex America recently introduced its Sysmex XP-300, an update for smaller labs in the U.S. and recently introduced to the Latin America and Caribbean market, as well as its Sysmex DI-60 integrated slide processing system, which provides seamless integration of automated slide making/staining and digital cell image classification. The Sysmex XP-300 automated hematology analyzer is part of the company’s three-part differential analyzer portfolio and combines the reliability and heritage of the KX-21N with updated, user-friendly software. The XP-300 has a

End-stage renal disease test, 9/13

EKF Diagnostics offers a novel test to accurately identify diabetic patients at high risk of progression to end-stage renal disease (ESRD) up to 10 years before currently available tests can. EKF’s sTNFr1 test is an ELISA assay that has the potential to significantly improve diabetic patient management and outcomes. The test accurately detects circulating levels of soluble tumor necrosis factor receptor 1 (sTNFr1) in patient samples. Research has demonstrated that high circulating levels of sTNFr1 are strongly associated with progression

Rapid strip-based hemoglobin test, 9/13

EKF Diagnostics offers its Stat-Site M Hgb strip-based test for quick and easy hemoglobin analysis for rapid anemia determination. Stat-Site M Hgb is a portable handheld analyzer. The pocket-sized device delivers accurate hemoglobin analysis results within 30 seconds from 15 µL of fingerstick whole blood. This hemoglobin photometer is maintenance-free and includes intuitive, step-by-step on-screen instructions to minimize operator training. Its durability, portability, and user-friendliness make the device especially suited to blood screening programs in developing world markets. It also

β-hydroxybutyrate strip test, 9/13

EKF Diagnostics’ Stat-Site M β-HB is a strip-based test for β-hydroxybutyrate that provides a quick and easy assessment of diabetic ketoacidosis (DKA), delivering results in less than 80 seconds. The presence and degree of ketosis can be assessed rapidly at the point of care by accurately measuring blood levels of β-HB, which accounts for 78 percent of the three ketone bodies, from 10 µL of serum or plasma. This results in useful information to provide quality care when monitoring DKA

DNA enrichment kits, 9/13

EKF Diagnostics offers its EKF Molecular Diagnostics’ PointMan DNA enrichment kits. The three kits are for enriching mutations in BRAF, KRAS, and EGFR T790M genes associated with skin melanoma and colorectal and lung cancers. PointMan kits provide highly specific and ultrasensitive enrichment of mutant genes in a background of wild-type (normal) genes. PointMan real-time PCR technology provides reliable and extremely sensitive detection for cancer mutations. The technology is highly efficient at amplifying the target sequence of interest, while suppressing amplification

Laboratory analyzer workflow interface, 9/13

The IVD Industry Connectivity Consortium (IICC) has developed a laboratory analyzer workflow (LAW) interface, which is a global interface based on a common set of clinical laboratory communications that unambiguously define communication protocols. In 2012, four diagnostic and three IT companies successfully validated 129 LAW tests. Since then, IICC has refined these interfaces and is asking more manufacturers to adopt the standard in an effort to simplify connectivity in the clinical laboratory and within the health care enterprise. Benefits of

Reference solutions for bath salt metabolites, 9/13

Cerilliant offers seven new certified spiking solutions of bath salt metabolites. The new products are 1.0 mg/mL (as free base) in methanol for the primary urinary metabolites of bath salt cathinones, mephedrone, buphedrone, pentedrone, flephedrone, N-ethylcathinone, and 4-methylethcathinone. For GC/MS and LC/MS methods that quantify concentrations of synthetic cathinone metabolites, the company also offers the corresponding deuterium-labeled internal standard. Cerilliant offers certified Snap-N-Spike solutions for use in clinical toxicology applications, medication monitoring, forensic analysis, employee drug screening, and urine drug

Reference solutions for thyroid hormones, 9/13

Cerilliant offers certified Snap-N-Spike solutions of thyroid hormones T4, T3, and reverse T3 at concentrations of 100 µg/mL in 0.1 N ammonia in methanol for each solution standard. These certified spiking solutions are for use as critical starting materials in the preparation of calibrators, controls, or linearity standards for analytical testing including LC-MS/MS analysis of free and total thyroid hormone levels. Comprehensive certificates of analysis (COAs) come with every Cerilliant certified reference standard and include all analytical data from full

MARKETPLACE

TRENDING